CORRESP Filing
Candel Therapeutics, Inc.
Date: Aug. 20, 2025 · CIK: 0001841387 · Accession: 0001193125-25-184067
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289595
Letter
Re: Candel Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 Filed August 14, 2025 File No. 333-289595 Ladies and Gentlemen, Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Candel Therapeutics, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to August 22, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Finn Murphy at (212) 459-7257. If you have any questions regarding this request, please contact William D. Collins of Goodwin Procter LLP at (617) 570-1447 or Finn Murphy at (212) 459-7257.
VIA EDGAR August 20, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549
Sincerely,
CANDEL THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR August 20, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Candel Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 Filed August 14, 2025 File No. 333-289595 Ladies and Gentlemen, Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Candel Therapeutics, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to August 22, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Finn Murphy at (212) 459-7257. If you have any questions regarding this request, please contact William D. Collins of Goodwin Procter LLP at (617) 570-1447 or Finn Murphy at (212) 459-7257. Sincerely, CANDEL THERAPEUTICS, INC. /s/ Paul Peter Tak Paul Peter Tak, M.D., Ph.D., FMedSci President and Chief Executive Officer cc: Charles Schoch, Candel Therapeutics, Inc. William D. Collins, Esq., Goodwin Procter LLP Finnbarr D. Murphy, Esq., Goodwin Procter LLP